Value through Innovation26 November 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients

- For media outside of the U.S., the UK & Canada only

ATS 2014
COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva®) alone

- For media outside UK, U.S. and Canada

Additional results from post-hoc analysis underline effectiveness of SPIRIVA®

- For ex-US and ex-UK Media Use Only  

IPF Phase III results published in NEJM show nintedanib* slows disease progression

- For non-US health media only

As the benefits and safety of Pradaxa® (dabigatran etexilate) are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa® to help more patients

- For media outside of the U.S., the UK & Canada only

New analysis shows Boehringer Ingelheim’s Giotrif® (afatinib) is the first treatment to demonstrate significant overall survival benefit for patients with a specific type of lung cancer

- For Ex-US and Ex-UK Media Only

Boehringer Ingelheim will make detailed clinical trial data available to the scientific community


New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

- For media outside of the U.S., the UK & Canada only

New registry data highlight substantial global differences in stroke prevention for patients with an irregular heart beat

- For media outside of the U.S., the UK & Canada only

Type 2 Diabetes Research: Connexios Life Sciences and Boehringer Ingelheim Enter Agreement for Novel AMPK Activators


Boehringer Ingelheim Animal Health announces the 2014 European PRRS Research Award


Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference

- For media outside UK, U.S. and Canada

Positive CHMP opinion for Pradaxa® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots

- For media outside of the U.S., the UK & Canada only

Hydra Biosciences and Boehringer Ingelheim announce worldwide collaboration to develop small-molecule inhibitors for the treatment of central nervous system diseases and disorders


Volasertib, Boehringer Ingelheim´s investigational treatment of acute myeloid leukaemia, is granted ‘orphan drug designation’ in the EU and the US

- For media outside of the US only

Boehringer Ingelheim receives “Facility of the Year Award” for Equipment Innovation in biopharmaceutical manufacturing


Boehringer Ingelheim pleased with 2013 financial year


Boehringer Ingelheim Animal Health supports PCV2 research projects with 500,000 euro